NCT04921904View on ClinicalTrials.gov

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Metastatic Esophageal AdenocarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Abemaciclib

150mg dose administered orally twice daily every day

DRUG

Ramucirumab

8mg/kg iv every 2 weeks until evidence of disease

Trial Locations (1)

75246

Baylor University Medical Center, Charles A Sammons Cancer Center, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER

NCT04921904 - Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | Biotech Hunter | Biotech Hunter